Discussions on the guideline recommendations for implantable cardioverter-defibrillator for the primary prevention of sudden cardiac death in patients with severe ventricular dysfunction. Consensus Document of the National Association of Hospital Cardiologists (ANMCO)/Italian Society of Cardiology (SIC)/Italian Association of Arrhythmology and Cardiac Pacing (AIAC);Considerazioni sulle raccomandazioni delle linee guida all'Impianto del cardioverter-defibrillatore per la prevenzione primaria della morte cardiaca improvvisa nei pazienti con grave disfunzione ventricolare. Documento di consenso dell'Assoc. Naz. Medici Cardiologi Ospedalieri (ANMCO)/Società Italiana di Cardiol. (SIC)/Assoc. Italiana di Aritmologia e Cardiostimolazione (AIAC)

Giornale Italiano di Cardiologia

Volumn 14, Issue 11, 2013, Pages 752-772

  Berisso, Massimo Zoni ^a   Bongiorni, Maria Grazia ^b   Curnis, Antonio ^c   Calvi, Valeria ^d   Catanzariti, Domenico ^e   Gaita, Fiorenzo ^f   Gulizia, Michele Massimo ^g   Inama, Giuseppe ^h   Landolina, Maurizio E ⁱ   La Rovere, Maria Teresa ^j   Mantovan, Roberto ^k   Mascioli, Giosuè ^l   Occhetta, Eraldo ^m   Padeletti, Luigi ⁿ   Salerno Uriarte, Jorge A ^o   Santini, Massimo ^p   Sassone, Biagio ^q   Senni, Michele ^r   Zecchin, Massimo ^s  

^a ASL 3 Genovese   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e Ospedale S Maria del Carmine   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g GARIBALDI HOSPITAL   (Italy)

^h OSPEDALE MAGGIORE   (Italy)

ⁱ FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^j IRCCS   (Italy)

^k Ospedale Bufalini   (Italy)

^l Humanitas Gavazzeni Hospital   (Italy)

^m Azienda Ospedaliera Universitaria Maggiore Della Carita   (Italy)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o UNIVERSITY OF INSUBRIA   (Italy)

^p SAN FILIPPO NERI HOSPITAL   (Italy)

^q Ospedale Clinicizzato SS Annunziata   (Italy)

^r OSPEDALI RIUNITI   (Italy)

^s UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

more..

Author keywords

Guidelines; Heart failure; Implantable cardioverter defibrillators; Prognosis; Sudden cardiac death; Tachyarrhythmias

Indexed keywords

CARDIOVERSION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DISEASE SEVERITY; HEART LEFT VENTRICLE FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PATIENT SELECTION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN CARDIAC DEATH;

DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VENTRICULAR DYSFUNCTION;

EID: 84890300341     PISSN: 18276806     EISSN: 19726481     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Bardy GH, Lee KL, Mark DB, et al.; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;20:225-37.
2. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-40.
3. Moss AJ, Zareba W, Hall WJ, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
4. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;337:1569-75.
5. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
6. Bristow MR, Saxon LA, Boehmer J, et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
7. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
8. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
9. Kurtz SM, Ochoa JA, Lau E, et al. Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993-2006. Pacing Clin Electrophysiol 2010;33: 705-11.
10. I Registri dell'Associazione Italiana di Aritmologia e Cardiostimolazione (AIAC). http://aiac.it/category/attivita/registri-aiac.
11. Al-Khatib SM, Hellkamp A, Curtis J, et al. Non-evidence-based ICD implantations in the United States. JAMA 2011;305:43-9.
12. Mehra MR, Yancy CW, Albert NM, et al Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: findings from IMPROVE HF. Heart Rhythm 2009;6:1727-34.
13. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52:1111-21.
14. Zoni Berisso, Caruso D, Canonero D, Setti S, Domenicucci S. Uso profilattico del cardioverter-defibrillatore impiantabile nei pazienti con grave disfunzione ventricolare sinistra: come districarsi tra linee guida, pratica clinica, problemi etici e limitazione delle risorse. G Ital Cardiol 2008;9:338-54.
15. Zoni Berisso M, Canonero D, Caruso D, Setti S, Domenicucci S. Terapia di risincronizzazione cardiaca in combinazione con la funzione di cardioversione-defibrillazione: considerazioni su una superiorità terapeutica ancora da dimostrare. G Ital Cardiol 2010;11:295-305.
16. Greenspon A, Patel JD, Lau E, et al. 16- year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011;58:1001-6.
17. van Rees JB, Borleffs CJ, de Bie MK, et al. Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality. J Am Coll Cardiol 2011;57:556-62.
18. Gould PA, Krahn AD; Canadian Heart Rhythm Society Working Group on Device Advisories. Complications associated with implantable cardioverter- defibrillator replacement in response to device advisories. JAMA 2006;295:1907-11.
19. Tung R, Swerdlow CD. Refining patient selection for primary prevention implantable cardioverter-defibrillator therapy: reeling in a net cast too widely. Circulation 2009;120:825-7.
20. Buxton AE. Should everyone with an ejection fraction ≤30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction ≤30% should receive an implantable cardioverter-defibrillator. Circulation 2005;111:2537-49.
21. Bracke FA, Dekker LR, van der Voort PH, Meijer A. Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest? Neth Heart J 2009;17:107-10.
22. Paperini L, Genovesi A, Carluccio M. La morte cardiaca improvvisa: prevenzione, quando opportuno! Da evidence-based medicine a family-based medicine. G Ital Cardiol 2006;7:224-7.
23. Tavazzi L. A proposito di defibrillatori impiantabili e linee guida. G Ital Cardiol 2006;7:228-33.
24. Inama G, Pedrinazzi C, Landolina M, et al.; ANMCO Arrhythmias, Heart Failure Areas. Use of implantable cardioverter-defibrillator and cardiac resynchronization therapy: an Italian survey study on 220 cardiology departments. J Cardiovasc Med 2012;13:675-83.
25. Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). Poll del Mese: Ritenete che le attuali linee guida sulle indicazioni all'ICD per la prevenzione primaria della morte cardiaca improvvisa diano risposte sufficientemente esaurienti ai dubbi quotidiani del cardiologo? http://www.tuttocuore.it/poll/default.html?ids=10 [ultimo accesso 10 settembre 2013].
26. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: Zipes DG, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: a Textbook of Cardiovascular Medicine. 7th edition. Philadelphia, PA: Elsevier-Saunders, 2005:865-908.
27. Fishman GI, Chung SS, DiMarco JP, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010;122:2335-48.
28. De Ferrari GM, Sanzo A. Epidemiologia. In: Santini M, ed. Trattato italiano di elettrofisiologia ed elettrostimolazione cardiaca. Vol 3. Aritmologia clinica. Torino: Centro Scientifico Editore, 2009:1185-90.
29. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large US community. J Am Coll Cardiol 2004;44:1268-75.
30. Eckart RE, Shry EA, Burke AP, et al.; Department of Defense Cardiovascular Death Registry Group. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011;58:1254-61.
31. Borjesson M, Pelliccia A. Incidence and aetiology of sudden cardiac death in young athletes: an international perspective. Br J Sports Med 2009;43:644-8.
32. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-51.
33. Krahn AD, Connolly SJ, Roberts RS, Gent M; ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. Am Heart J 2004;147:837-40.
34. Davies MJ. Anatomic features in victims of sudden coronary death. Coronary artery pathology. Circulation 1992;85(1 Suppl):I19-24.
35. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Circulation 2000;102:611-6.
36. Mehta D, Carwin J, Gomes JA, Fuster V. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation 1997;96:3215-23.
37. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-63.
38. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML; MADIT-II Investigators. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004;43:1459-65.
39. Cleland JG, Thygesen K, Uretsky BF, et al.; ATLAS Investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J 2001;22:1601-12.
40. Kadish A, Dyer A, Daubert JP, et al.; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350: 2151-8.
41. Grimm W, Christ M, Bach J, Muller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003;108:2883-91.
42. Haïssaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008;358:2016-23.
43. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
44. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
45. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54.
46. Young JB, Abraham WT, Smith AL, et al.; Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE ICD) Trial Investigators. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 2003;289:2685-94.
47. Moss AJ, Hall WJ, Cannom DS, et al.; MADIT-CRT Trial Investigators. Cardiac resynchronization therapy for the prevention of heart failure events. N Engl J Med 2009;361:1329-38.
48. Tang AS, Wells GA, Talajic M, et al.; Re-synchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-95.
49. Wathen MS, Sweeney MO, DeGroot PJ, et al.; PainFREE Investigators. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001;104:796-801.
50. Gulizia MM, Piraino L, Scherillo M, et al.; PITAGORA ICD Study Investigators. A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators: the PITAGORA ICD trial. Circ Arrhythm Electrophysiol 2009;2:146-53.
51. Wilkoff BL, Williamson BD, Stern RS, et al.; PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol 2008;42:541-50.
52. Gasparini M, Menozzi C, Proclemer A, et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft ventriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. Eur Heart J 2009;30:2758-67.
53. Goldenberg I, Gillespie J, Moss AJ, et al.; Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010;122:1265-71.
54. Moss AJ. What we have learned from the family of multicenter automatic defibrillator implantation trials. Circ J 2010;74:1038-41.
55. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353:1471-80.
56. Goldenberg I, Moss AJ, McNitt S, et al.; MADIT-II Investigators. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:1811-7.
57. Mozaffarian D, Anker SD, Anand I, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007;116:392-8.
58. Goldenberg I, Vyas AK, Hall WJ, et al.; MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-96.
59. Buxton AE, Lee KL, Hafley GE, Prystowsky EN, et al. A simple model using the MUSTT database can stratify total mortality and sudden death risk of coronary disease patients [abstract]. J Am Coll Cardiol 2004;43:425A.
60. Bleeker SE, Moll HA, Steyerberg EW, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 2003;56:826-32.
61. Kramer DB, Friedman PA, Kallinen LM, et al. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm 2012;9:42-6.
62. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424-33.
63. Vazquez R, Bayes-Genis A, Cygankiewicz I, et al.; MUSIC Investigators. The MUSIC Risk score: a simple method for predicting mortality in ambulatory patients with chronic heart failure. Eur Heart J 2009;30:1088-96.
64. Senni M, Santilli G, Parrella P, et al. A novel prognostic index to determine the impact of cardiac conditions and co-morbidities on one-year outcome in patients with heart failure. Am J Cardiol 2006;98:1076-82.
65. Senni M, Parrella P, De Maria R, et al. Predicting heart failure outcome from cardiac and comorbid conditions: the 3C-HF score. Int J Cardiol 2013;163:206-11.
66. Agostoni P, Corrà U, Cattadori G, et al.; MECKI Score Research Group. Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: a multiparametric approach to heart failure prognosis. Int J Cardiol 2013;167:2710-8.
67. Pocock SJ, Ariti CA, McMurray JJ, et al.; Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013;34:1404-13.
68. Clemens M, Szegedi Z, Kardos L, et al. The Settle Heart Failure Model predicts survival in patients with cardiac resynchronization therapy: a validation study. J Card Fail 2012;18:682-7.
69. Smith T, Levy WC, Schaer BA, et al. Performance of the Seattle Heart Failure Model in implantable defibrillator patients treated with cardiac resynchronization therapy. Am J Cardiol 2012;110:398-402.
70. Buxton AE, Lee KL, Hafley GE, et al.; MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 2007;50:1150-7.
71. Goldberger JJ. Evidence-based analysis of risk factors for sudden cardiac death. Heart Rhythm 2009;6(3 Suppl):S2-7.
72. Buxton AE. Risk stratification for sudden death in patients with coronary artery disease. Heart Rhythm 2009;6:836-47.
73. Clarke B, Howlett J, Sapp J, Andreou P, Parkash R. The effect of comorbidity on the competing risk of sudden and nonsudden death in an ambulatory heart failure population. Can J Cardiol 2011;27:254-61.
74. Salerno-Uriarte JA, De Ferrari GM, Klersy C, et al.; ALPHA Study Group Investigators. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol 2007;50:1896-904.
75. La Rovere MT, Pinna GD, Hohnloser SH, et al.; ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001;103:2072-7.
76. Huikuri HV, Raatikainen MJ, Moerch-Joergensen R, et al.; Cardiac Arrhythmias and Risk Stratification after Acute Myocardial Infarction Study Group. Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur Heart J 2009;30:689-98.
77. Merchant FM, Ikeda T, Pedretti RF, et al. Clinical utility of microvolt T-wave alternans testing in identifying patients at high or low risk of sudden cardiac death. Heart Rhythm 2012;9:1256-64.e2.
78. Exner DV, Kavanagh KM, Slawnych MP, et al.; REFINE Investigators. Noninvasive risk assessment early after a myocardial infarction: the REFINE study. J Am Coll Cardiol 2007;50:2275-84.
79. Bailey JJ, Hodges M, Church TR. Decision to implant a cardioverter defibrillator after myocardial infarction: the role of ejection fraction vs other risk factor markers. Med Decis Making 2007;27:151-60.
80. Wellens HJ, Schuilenburg RM, Durrer D. Electrical stimulation of the heart in patients with ventricular tachycardia. Circulation 1972;46:216-26.
81. Thomas KE, Josephson ME. The role of electrophysiology study in risk stratification of sudden cardiac death. Prog Cardiovasc Dis 2008;51:97-105.
82. Mason JW, Winkle RA. Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation 1978;58:971-85.
83. Zoni-Berisso M, Molini D, Mela GS, Vecchio C. Value of programmed ventricular stimulation in predicting sudden death and sustained ventricular tachycardia in survivors of acute myocardial infarction. Am J Cardiol 1996;77:673-80.
84. Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983;308:1436-42.
85. Wyse DG, Talajic M, Hafley GE, et al. Antiarrhythmic drug therapy in the Multicenter UnSustained Tachycardia Trial (MUSTT): drug testing and as-treated analysis. J Am Coll Cardiol 2001;38:344-51.
86. Schlapfer J, Rapp F, Kappenberger L, Fromer M. Electrophysiologically guided amiodarone therapy versus the implantable cardioverter-defibrillator for sustained ventricular tachyarrhythmias after myocardial infarction: results of long-term follow-up. J Am Coll Cardiol 2002;39:1813-9.
87. Buxton AE, Lee KL, Hafley GE, et al.; MUSTT Investigators. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the Multicenter UnSustained Tachycardia Trial. Circulation 2002;106:2466-72.
88. Daubert JP, Zareba W, Hall WJ, et al.; MADIT II Study Investigators. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2006;47:98-107.
89. De Ferrari GM, Rordorf R, Frattini F, Petracci B, De Filippo P, Landolina M. Predictive value of programmed ventricular stimulation in patients with ischaemic cardiomyopathy: implications for the selection of candidates for an implantable defibrillator. Europace 2007;9:1151-7.
90. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746-837.
91. Brembilla-Perrot B, Suty-Selton C, Beurrier D, et al. Differences in mechanisms and outcomes of syncope in patients with coronary disease or idiopathic left ventricular dysfunction as assessed by electrophysiologic testing. J Am Coll Cardiol 2004;44:594-601.
92. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 2002;105:1453-8.
93. Grimm W, Hoffmann J, Menz V, Luck K, Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol 1998;32:739-45.
94. Kron J, Hart M, Schual-Berke S, Niles NR, Hosenpud JD, McAnulty JH. Idiopathic dilated cardiomyopathy. Role of programmed electrical stimulation and Holter monitoring in predicting those at risk of sudden death. Chest 1988;93:85-90.
95. Meinertz T, Treese N, Kasper W, et al. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. Am J Cardiol 1985;56:337-41.
96. Lunati M, Santini M, Bongiorni MG, et al. Linee guida AIAC all'impianto di pacemaker, dispositivi per la resincronizzazione cardiaca, defibrillatori automatici e loop recorder - update 2011. Giornale Italiano di Aritmologia e Cardiostimolazione 2011;14:1-62.
97. Ypenburg C, van Erven L, Bleeker GB, et al. Benefit of combined resynchronization and defibrillator therapy in heart failure patients with and without ventricular arrhythmias. J Am Coll Cardiol 2006;48:464-70.
98. Higgins SL, Yong P, Sheck D, et al. Biventricular pacing diminishes the need for implantable cardioverter defibrillator therapy. Ventak CHF Investigators. J Am Coll Cardiol 2000;36:824-7.
99. Verhaert D, Grimm RA, Puntawangkoon C, et al. Long-term reverse remodeling with cardiac resynchronization therapy: results of extended echocardiographic follow-up. J Am Coll Cardiol 2010;55:1788-95.
100. Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007;335:925.
101. Cleland JG, Daubert JC, Erdmann E, et al.; Cardiac Resynchronization- Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
102. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006;27:1928-32.
103. Landolina M, Gasparini M, Lunati M, et al.; InSync/InSync ICD Italian Registry Investigators. Heart rate variability monitored by implanted device predicts response to CRT and long-term clinical outcome in patients with advanced heart failure. Eur J Heart Fail 2008;10:1073-9.
104. Gold MR, Linde C, Abraham WT, Gardiwal A, Daubert JC. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm 2011;8:679-84.
105. Lin G, Rea RF, Hammill SC, Hayes DL, Brady PA. Effect of cardiac resynchronisation therapy on occurrence of ventricular arrhythmia in patients with implantable cardioverter defibrillators undergoing upgrade to cardiac resynchronisation therapy devices. Heart 2008;94:186-90.
106. Di Biase L, Gasparini M, Lunati M, et al.; InSync/InSync ICD Italian Registry Investigators. Antiarrhythmic effect of reverse ventricular remodeling induced by cardiac resynchronization therapy: the InSync ICD (Implantable Cardioverter-Defibrillator) Italian Registry. J Am Coll Cardiol 2008;52:1442-9.
107. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-87.
108. van Veldhuisen DJ, Maass AH, Priori SG, et al. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009;11:1143-51.
109. Swindle JP, Rich MW, McCann P, Burroughs TE, Hauptman PJ. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med 2010;170:631-7.
110. Santangeli P, Di Biase L, Dello Russo A, et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med 2010;153:592-9.
111. Proclemer A, Ghidina M, Gregori D, et al. Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-07. Europace 2009;11:465-75.
112. Santangeli P, Pelargonio G, Dello Russo A et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm 2010;7:876-82.
113. Kannel WB, Wilson PW, D'Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998;136:205-12.
114. Kong MH, Al-Khatib SM, Sanders GD, Hasselblad V, Peterson ED. Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. Cardiol J 2011;18:503-14.
115. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209.
116. Ko DT, Alter DA, Austin PC, et al. Life expectancy after an index hospitalization for patients with heart failure: a population-based study. Am Heart J 2008;155:324-31.
117. Cutro R, Rich MW, Hauptman PJ. Device therapy in patients with heart failure and advanced age: too much too late? Int J Cardiol 2012;155:52-5.
118. Levy WC, Lee KL, Hellkamp AS, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009;120:835-42.
119. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007;49:2408-15.
120. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 2006;151:397-403.
121. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
122. Lindenfeld J, Feldman AM, Saxon L, et al. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure. Circulation 2007;115:204-12.
123. Singh SN, Poole J, Anderson J, et al.; SCD-HeFT Investigators. Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. Am Heart J 2006;152:974.e7-11.
124. Zareba W, Steinberg JS, McNitt S, Daubert JP, Piotrowicz K, Moss AJ; MADIT II Investigators. Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. Heart Rhythm 2006;3:631-7.
125. Hohnloser SH, Kuck KH, Dorian P, et al.; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-8.
126. Zecchin M, Merlo M, Pivetta A, et al. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?". Am J Cardiol 2012;109:729-35.
127. Peterson PN, Daugherty SL, Wang Y, et al.; National Cardiovascular Data Registry. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. Circulation 2009;119:1078-84.
128. van Rees JB, de Bie MK, Thijssen J, Borleffs CJ, Schalij MJ, van Erven L. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol 2011;58:995-1000.
129. Landolina M, Gasparini, M, Lunati, M, et al.; Cardiovascular Centers Participating in the Clinical Service Project. Long-term complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database. Circulation 2011;123:2526-35.
130. Poole JE, Gleva MJ, Mela T, et al.; REPLACE Registry Investigators. Complication rates associated with pacemaker or implantable cardioverter- defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553-61.
131. Krahn AD, Lee DS, Birnie D, et al.; Ontario ICD Database Investigators. Predictors of short-term complications after implantable cardioverter- defibrillator replacement: results from the Ontario ICD Database. Circ Arrhythm Electrophysiol 2011;4:136-42.
132. Goette A, Cantu F, van Erven L, et al. Performance and survival of transvenous defibrillation leads: need for a European data registry. Europace 2009;11:31-4.
133. Moss AJ, Greenberg H, Case RB, et al.; Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation 2004;110:3760-5.
134. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Am Coll Cardiol 2011;58:1007-13.
135. Haines DE, Wang Y, Curtis J. Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation 2011;123:2069-76.
136. Padeletti L, Arnar DO, Boncinelli L, et al.; European Heart Rhythm Association; Heart Rhythm Society. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010;12:1480-9.
137. Wilkoff BL, Auricchio A, Brugada J, et al. HRS/EHRA Expert Consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association. Europace 2008;10:707-25.
138. Mueller PS, Jenkins SM, Bramstedt KA, Hayes DL. Deactivating implanted cardiac devices in terminally ill patients: practices and attitudes. Pacing Clin Electrophysiol 2008;31:560-8.
139. Mueller PS, Hook CC, Hayes DL. Ethical analysis of withdrawal of pacemaker or implantable cardioverter-defibrillator support at the end of life. Mayo Clin Proc 2003;78:959-63.
140. Brunner-La Rocca HP, Rickenbacher P, Muzzarelli S, et al.; TIME-CHF Investigators. End-of-life preferences of elderly patients with chronic heart failure. Eur Heart J 2012;33:752-9.
141. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50 000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56.
142. Bond M, Mealing S, Anderson R, Dean J, Stein K, Taylor RS. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction? Int J Cardiol 2009;137:206-15.
143. Holzmeister J, Leclercq C. Implantable cardioverter defibrillators and cardiac resynchronisation therapy. Lancet 2011;378:722-30.
144. Cuculich PS, Joseph S. Cardiac resynchronization therapy: what? Who? When? How? Am J Med 2011;124:813-5.
145. Santini M, Cappato R, Andresen D, et al. Current state of knowledge and experts' perspective on the subcutaneous implantable cardioverter-defibrillator. J Interv Card Electrophysiol 2009;25:83-8.
146. Martins RP, Baruteau AE, Treguer F, et al. Magnetic resonance imaging in patients with pacemakers and implantable cardioverter-defibrillators: a systematic review. Ann Cardiol Angeiol 2010;59:221-8.
147. Dubner S, Auricchio A, Steinberg JS, et al. ISHNE/EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Europace 2012;14:278-93.